A new publication titled "[Pathophysiological aspects of primary Sjögren's disease: From epithelial activation to systemic autoimmunity]" was published on September 1, 2026. The article appeared in Zeitschrift fur Rheumatologie, a peer reviewed journal covering rheumatology topics.
This entry is indexed under the compound selank, which remains classified as unapproved and is used only in a research context. The publication record does not include findings, conclusions, or data summaries beyond the title itself.
No results, outcomes, or safety information from this publication are described in the available event data. As such, no claims about efficacy, benefit, or clinical relevance can be made at this time.
Readers interested in the broader context of ongoing research and publications related to selank can consult the compound overview for additional background.